IDYA IDEAYA Biosciences, Inc.
FY2025 10-K
IDEAYA Biosciences, Inc. (IDYA) filed its fiscal year 2025 10-K annual report with the SEC on Feb 17, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core oncology precision medicine with focus on synthetic lethality and antibody-drug conjugates (ADCs) targeting molecularly defined solid tumors
- • New Phase 3 neoadjuvant trial for darovasertib in primary uveal melanoma initiated, targeting eye preservation and vision improvement
Management Discussion & Analysis
- • Collaboration revenue $218.7M in 2025 vs $7.0M in 2024, up 3,024% driven by Servier License Agreement
- • Net loss $113.7M in 2025 vs $274.5M in 2024; loss decreased 59%, operating expenses up 13% to $378.0M
Risk Factors
- • Regulatory risk: Servier License Agreement contract assets increased $6.0M, indicating dependency on this agreement's terms and regulatory compliance timing
- • Macroeconomic threat: Operating cash used $71.1M in 2025 and $247.6M in 2024, showing high cash burn amid volatile financing environment
Financial SummaryXBRL
Revenue
$219M
Net Income
-$114M
Operating Margin
-72.8%
Net Margin
-52.0%
ROE
-11.1%
Total Assets
$1.1B
EPS (Diluted)
$-1.28
Operating Cash Flow
-$71M
Source: XBRL data from IDEAYA Biosciences, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on IDEAYA Biosciences, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.